Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MERTK | Q12866 | 14/20 | 0.61 |
| ▸ | TYRO3 | Q06418 | 13/20 | 0.41 |
| ▸ | AXL | P30530 | 5/20 | 0.41 |
| ▸ | SYK | P43405 | 1/20 | 0.41 |
| ▸ | GAS6 | Q14393 | 8/20 | 0.40 |
| ▸ | FLT3 | P36888 | 8/20 | 0.40 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.39 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2901084 | 0.89 | MERTK (0.49) | MERTKTYRO3AXLSYKGAS6 | |
| SCHEMBL2898749 | 0.87 | MERTK (0.47) | MERTKSYKTLR8TLR7 | |
| SCHEMBL2902620 | 0.83 | MERTK (0.60) | MERTKTYRO3AXLSYKGAS6 | |
| SCHEMBL2899621 | 0.80 | MERTK (0.44) | MERTK | |
| SCHEMBL2901196 | 0.78 | KDM6B (0.46) | MERTKTYRO3AXLGAS6FLT3 | |
| SCHEMBL2902684 | 0.73 | MERTK (0.49) | MERTKTYRO3AXLSYKGAS6 | |
| SCHEMBL2903504 | 0.72 | REN (0.53) | MERTKTYRO3GAS6FLT3 | |
| SCHEMBL2897231 | 0.71 | HRH4 (0.40) | TYRO3FLT3KCNH2 | |
| SCHEMBL2900049 | 0.71 | MERTK (0.47) | MERTK | |
| SCHEMBL2900591 | 0.68 | REN (0.53) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2202228-B1 | AMIDE COMPOUNDS AND USE OF THE SAME | TAKEDA PHARMACEUTICAL (JP) | 2014-12-10 | — | — | EP | disclosed |
| US-8329691-B2 | Amide compounds and use of the same | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-12-11 | — | — | US | disclosed |
| US-8329691-B2 | Amide compounds and use of the same | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-12-11 | — | — | US | disclosed |
| US-8329691-B2 | Amide compounds and use of the same | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-12-11 | — | — | US | disclosed |
| US-20100324010-A1 | AMIDE COMPOUNDS AND USE OF THE SAME | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-12-23 | — | — | US | disclosed |
| US-20100324010-A1 | AMIDE COMPOUNDS AND USE OF THE SAME | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-12-23 | — | — | US | disclosed |
| US-20100324010-A1 | AMIDE COMPOUNDS AND USE OF THE SAME | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-12-23 | — | — | US | disclosed |
| EP-2202228-A1 | AMIDE COMPOUNDS AND USE OF THE SAME | Takeda Pharmaceutical Company Limited (JP) | 2010-06-30 | — | — | EP | disclosed |
| EP-2202228-A1 | AMIDE COMPOUNDS AND USE OF THE SAME | Takeda Pharmaceutical Company Limited (JP) | 2010-06-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324010-A1 | AMIDE COMPOUNDS AND USE OF THE SAME | REN, ACE, AGT | MERTK 3317/4885TYRO3 3003/4885AXL 2315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.